NASDAQ:TELA • US8723811084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TELA BIO INC (TELA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-03-25 | Lake Street | Maintains | Buy -> Buy |
| 2026-03-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-25 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-12-01 | Lake Street | Maintains | Buy -> Buy |
| 2025-11-18 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-11-14 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-14 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-03-21 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-03-21 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-21 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-11-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-10-04 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-13 | Lake Street | Maintains | Buy -> Buy |
| 2024-08-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-08-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-07-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-22 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-22 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-12-27 | Lake Street | Reiterate | Buy -> Buy |
| 2023-11-10 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-03-28 | Canaccord Genuity | Reiterate | Buy |
| 2023-03-22 | JMP Securities | Reiterate | Market Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 58.453M 41.12% | 69.3M 18.56% | 80.275M 15.84% | 94.527M 17.75% | 110.08M 16.45% | 128.94M 17.13% | |
| EBITDA YoY % growth | -43.267M -14.37% | -40.683M 5.97% | -32.745M 19.51% | -22.431M 31.50% | -11.639M 48.11% | 9.934M 185.35% | |
| EBIT YoY % growth | -44.075M -12.98% | -41.695M 5.40% | -33.755M 19.04% | -27.282M 19.18% | -15.429M 43.45% | 1.962M 112.72% | |
| Operating Margin | -75.40% | -60.17% | -42.05% | -28.86% | -14.02% | 1.52% | |
| EPS YoY % growth | -2.07 23.33% | -1.39 32.85% | -0.82 41.01% | -0.60 27.08% | -0.40 33.34% | -0.07 83.37% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 34.41% | -0.15 30.80% | -0.14 27.53% | -0.12 25.41% | -0.10 40.28% | -0.09 41.71% | -0.08 39.63% | -0.08 35.04% |
| Revenue Q2Q % growth | 21.703M 17.19% | 23.044M 14.10% | 24.26M 17.26% | 25.559M 22.47% | 25.021M 15.29% | 27.209M 18.07% | 28.473M 17.37% | 29.371M 14.91% |
| EBITDA Q2Q % growth | -5.466M 46.44% | -4.778M 44.08% | -4.171M 38.38% | -2.704M 52.04% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.283M 20.91% | -7.543M 16.93% | -6.117M 19.02% | -4.948M 25.57% | N/A | N/A | N/A | N/A |
All data in USD
11 analysts have analysed TELA and the average price target is 3.52 USD. This implies a price increase of 522.94% is expected in the next year compared to the current price of 0.5649.
TELA BIO INC (TELA) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of TELA BIO INC (TELA) is -0.16 USD and the consensus revenue estimate is 21.70M USD.
The consensus rating for TELA BIO INC (TELA) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.